FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Aviva Launches Insurance App on ChatGPT, Enhancing Customer Interactions

The new app aims to simplify insurance queries and support for users.Highlights: Aviva introduces an insurance app on...
FinTech

NatWest Strengthens Mortgage Offerings with Pexa Digital Platform

Banking giant NatWest implements Pexa platform for streamlined digital mortgages.Highlights: NatWest integrates Pexa's platform for digital mortgages.The initiative...
FinTech

Visa Strengthens Role as Super Validator in Canton Network

Visa's new position enhances blockchain transaction verification in the Canton network.Highlights: Visa becomes a super validator within the...
FinTech

Monument Bank to Tokenise Retail Deposits, Enhancing Digital Banking Access

New initiative aims to modernize retail banking and improve deposit management.Highlights: Monument Bank plans to tokenize retail deposits...